Artificial Pancreas Device Systems (APDS) Market - By Device Type (Threshold Suspend Device Systems, Control-to-range (CTR) Systems, Control-to-target (CTT) Systems), By End-use (Hospitals and Clinics, Homecare) – Global Forecast, 2023-2032

Artificial Pancreas Device Systems Market Size

Artificial Pancreas Device Systems Market size was valued at USD 331 million in 2022 and is estimated to account for USD 757.5 million by 2032. Increasing number of people suffering from chronic conditions such as obesity resulting in occurrence of diabetes will act as a primary factor for driving market demand.
 

For instance, according to official statistics, over 80% of people suffering from Type 2 diabetes are obese. An artificial pancreas device system (APDS) is a medical device designed for individuals with diabetes. It combines a continuous glucose monitor (CGM), the market of which is projected to reach USD 21.4 billion by 2032, an insulin pump, and a computer algorithm to automatically regulate blood glucose levels. The system continuously monitors glucose levels and adjusts insulin delivery in real-time, mimicking the function of healthy pancreas.
 

Factors such as sedentary lifestyle, unhealthy diet, and an aging population base contribute to the rising incidence of both type 1 and type 2 diabetes. For instance, as per the report of International Diabetes Federation's Diabetes Atlas 10th edition, the number of adults (aged 20-79) suffering from diabetes is anticipated to surge to 783.2 million by 2045. These statistics underscore the escalating worldwide burden of diabetes and its significant impact on public health. Therefore, there is an urgent need for effective and efficient methods to manage the disease. APDS offers a promising solution by automating glycemic control, helping patients maintain stable blood glucose levels. Furthermore, prominent medical device companies are heavily investing in APDS technology leading to the development of more advanced, user-friendly systems, improving performance, patient outcomes, and market adoption, ultimately driving market expansion.
 

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the APDS market. Disruptions in supply chains, healthcare resource allocation, and economic uncertainties led to delays in APDS production and adoption. Additionally, clinical trials and research were also affected, while regulatory delays hindered market entry. Additionally, patient concerns about visiting healthcare facilities during the pandemic further reduced APDS utilization. Thus, these combined factors created a challenging environment for the APDS market, negatively impacting its growth and adoption during the pandemic.
 

Artificial Pancreas Device Systems Market Trends

Rising demand for automated glycemic control systems such as APDS, technological advancements in CGM sensors, and increase in investment towards research and development by key players is driving the market progress. Technological improvements have transformed CGM sensors into smaller, more accurate, and less invasive devices, greatly enhancing patient comfort and overall usability. This heightened accuracy ensures that APDS can make precise insulin dosing adjustments, resulting in improved glycemic control and a reduced risk of hypoglycemia and hyperglycemia. As these technological advancements expand the appeal of APDS to a broader user base and gain increased clinical endorsement.
 

Traditional diabetes management methods involve multiple daily injections or manual adjustments of insulin doses, that can be burdensome and challenging for patients to maintain consistently. Thus, the demand for automated systems such as APDS is increasing among diabetic patients. Moreover, as demand increases, medical device companies are focusing on developing more advanced solutions, which can be another factor in the high adoption of APDS. For instance, the Medtronic MiniMed 780G artificial pancreas system has received approval from the Food and Drug Administration (FDA) for use in individuals aged 7 and above. This system offers automatic adjustments and real-time corrections to blood sugar levels at 5-minute intervals, including correction doses, as part of its meal detection technology.
 

Artificial Pancreas Device Systems Market Analysis:

The market by device type is categorized into threshold suspend device systems, control-to-range (CTR) systems, control-to-target (CTT) systems. The threshold suspends device systems segment garnered USD 175 million revenue size in the year 2022. The dominance of the segment can be attributed to their advanced safety features.
 

• These systems automatically suspend insulin delivery while blood glucose levels reach a predetermined threshold, effectively preventing a life-threatening condition.
   
• The safety aspect strongly resonates with both healthcare providers and patients, thereby increasing the adoption of APDS.
   

Thus, the reduced hypoglycemic events and enhanced patient safety has been a key driver for market development.
 

Based on end-use, the artificial pancreas device systems market is segmented into hospitals and clinics, homecare, and others. The hospitals and clinics segment garnered USD 102 million revenue size in the year 2022.
 

• Growth of hospital and clinics segment can be attributed to their clinical expertise, ability to provide continuous patient monitoring, access to advanced medical technology, active involvement in research and clinical trials, facilitation of insurance coverage, and their crucial role in patient education and awareness.
   
• The presence of skilled healthcare professionals in these settings ensures proper training and support for APDS users, enhancing patient safety and comfort.
   
• Additionally, hospitals and clinics serve as hubs for critical research that validate the effectiveness of APDS, thereby promoting greater clinical endorsement and market demand.
   
• Their established relationships with insurance providers further encourage patients to adopt APDS, making it a preferred choice for diabetes management.
   

Therefore, segments contributions create a conducive environment for APDS adoption and contribute significantly to the market size.
 

U.S. artificial pancreas device systems market accounted for USD 122 million revenue size in 2022 and is predicted to witness substantial market growth.
 

• Surge in the diabetes population base in the U.S. is one of the primary factors driving the market expansion in the country.
   
• The presence of a stringent but well-defined regulatory framework by the U.S. FDA ensures safety and efficacy of artificial pancreas device systems, instilling confidence in healthcare providers and patients alike
   
• Additionally, greater patient awareness, access to healthcare, health insurance coverage, and a growing demand for advanced diabetes management solutions have all played a pivotal role in propelling the market's trends and establishing the U.S. as a dominant force in this vital healthcare sector.
   

Artificial Pancreas Device Systems Market Share

The ADPS industry is consolidated in nature with major companies competing to offer superior APDS in this business space. Medtronic Plc, Johnson & Johnson Services Inc, Bigfoot Biomedical, Tandem Diabetes Care, Inc., Pancreum, Inc, etc. are some of the major players holding majority of share in this market. These companies are focusing their efforts on continuous product innovation in order to acquire substantial market share. For instance, Medtronic Plc is engaged in developing advanced artificial pancreas system. Other companies such as Johnson & Johnson Services Inc, Bigfoot Biomedical are focusing on bringing advanced products to the market to gain competitive advantage and expand their client base. The major strategies adopted by the company involves geographical expansion, new product launch, distribution agreements, etc.
 

Some of the eminent market participants operating in in the artificial pancreas device systems industry include:

• Medtronic Plc
• Johnson & Johnson Services Inc
• Bigfoot Biomedical
• Tandem Diabetes Care, Inc.
• Pancreum, Inc.
• TypeZero Technologies, LLC
• Beta Bionics
• Insulet Corporation
• Defymed
• Inreda Diabetic
• Diabeloop
   

Artificial Pancreas Device Systems Industry News:

• In April 2023, Medtronic’s MiniMed 780G artificial pancreas system received approval from the FDA for use in individuals aged 7 and above. This system offers automatic adjustments and real-time corrections to blood sugar levels at 5-minute intervals, including correction doses, as part of its meal detection technology. This approval expanded the company's product portfolio and significantly increased its business revenue.
   

Artificial pancreas device systems market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD and volume in Units from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Device Type, 2018-2032 (USD Million & Units)

• Threshold suspend device systems
• Control-to-range (CTR) systems
• Control-to-target (CTT) systems

By End-use, 2018-2032 (USD Million)

• Hospitals and clinics
• Homecare
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa